Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.

Larsen, Claus M; Faulenbach, Mirjam; Vaag, Allan; Ehses, Jan A; Donath, Marc Y; Mandrup-Poulsen, Thomas
Diabetes care; 2009 Sep;32(9):1663-8. PMID: 19542207
Hagedorn Research Institute and Steno Diabetes Center, Gentofte, Denmark.


Interleukin (IL)-1 impairs insulin secretion and induces beta-cell apoptosis. Pancreatic beta-cell IL-1 expression is increased and interleukin-1 receptor antagonist (IL-1Ra) expression reduced in patients with type 2 diabetes. Treatment with recombinant IL-1Ra improves glycemia and beta-cell function and reduces inflammatory markers in patients with type 2 diabetes. Here we investigated the durability of these responses.